arrow
A

Amarnath Challapalli

University Hospitals Bristol and Weston NHS Foundation Trust
H指数:18
被引数:1,234

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer – a multicentre evaluation

前列腺癌中[18F]PSMA-1007 PET/CT显像中PSMA-RADS版本2.0与骨摄取转移概率(BUMP)评分对特征性骨摄取的比较分析——一项多中心评估

2026-09-010
OAAI
NHS England and British Uro-oncology Group Survey: National Insights into Radiotherapy pathway timings for intermediate and high-risk prostate cancer

英国国家医疗服务体系与英国泌尿肿瘤学组调查:针对中高风险前列腺癌放疗路径时长的国家洞察

2026-05-220
PRE
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations

在晚期肾细胞癌中优化预后:国际真实世界数据验证Meet-URO评分在一线免疫治疗联合方案中的应用

2026-05-200
OA
Corrigendum to “Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer” [Radiother. Oncol. 216 (2026) 111385]

勘误:来自一项关于使用单次19 Gy剂量进行高剂量率单次治疗局部前列腺癌的多中心研究的长期结果 [Radiother. Oncol. 216 (2026) 111385]

2026-04-090
PRE
Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?

真实世界数据对转移性肾癌治疗模式的挑战:是时候区分IMDC中危/高危组了吗?

2024-09-010
PRE
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts
2024-07-030
OAAI
Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

177Lu-PSMA治疗的资格取决于伴侣诊断示踪剂的选择: 转移性去势抵抗性前列腺癌中68Ga-PSMA-11和99mTc-MIP-1404的比较

2022-10-277
OAAI